Slingshot members are tracking this event:

Merck (MRK) Expects to File NDA for DPP-4 Inhibitor Omarigliptin in Treatment of Type 2 Diabetes by End of 2016 - Cancelled

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nda, Dpp-4 Inhibitor, Omarigliptin, Type 2 Diabetes